# MONOLISA™ Anti-HAV IgM EIA 510(k) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

510(k) Number:   
510(k) Summary Report Date:

K 063319

April, 2007

MANUFACTURER INFORMATION

MANUFACTURER ADDRESS:

Bio-Rad 3, Boulevard Raymond Poincaré 92430 Marnes-la-Coquette, France

# TELEPHONE :

00 33 1 47 95 60 00

8023060

OWNER/OPERATOR :

Bio-Rad 3, Boulevard Raymond Poincare 92430 Marnes-la-Coquette, France

8023061

OFFICIAL CORRESPONDENT ADDRESS :

Bio-Rad 3, Boulevard Raymond Poincaré 92430 Marnes-la-Coquette, France

# TELEPHONE:

00 33 1 47 95 60 00

Mrs. Sylvie Confida

TELEPHONE : FAX :

00 33 1 47 95 61 38   
00 33 1 47 95 62 42

CLASSIFICATION INFORMATION

CLASSIFICATION NAME: COMMON NAME: PRODUCT TRADE NAME: DEVICE CLASS :

Hepatitis A Test (IgM Antiody IgM Antibody to Hepatitis A Virus MONOLISA™ Anti-HAV IgM EIA Class II LOL

CLASSIFICATION PANEL : Immunology and Microbiology Devices REGULATION NUMBER : 21 CFR 866.3310

# LEGALLY MARKETED EQUIVALENT (SE) DEVICE

DiaSorin ETI-HA-IGMK PLUS PMA Number : P890014 Decision Date : 12/14/2005

# DEVICE DESCRIPTION

The MONOLISA™ Anti-HAV IgM EIA is an enzyme immunoassay (IgM antibdy capture format) for the detection of IgM antibodies to Hepatitis A Virus. In the assay procedure, patient specimens, a calibrator, and controls are incubated with anti-human IgM antibodies coated on the microwells. If IgM antibodies to HAV are present in a specimen or control, they bind to the antibody. Excess sample is removed by a wash step. The HAV Viral Antigen and the Conjugate (containing horseradish peroxidase  labeled mouse monoclonal antibody to HAV) are successively added to the microwells and allowed to incubate. The presence of IgM anti-HAV in the sample enables the HAV Viral Antigen and the Conjugate to bind to the solid phase. Excess Conjugate and HAV Viral Antigen are removed by a wash step, and a TMB Chromogen / Substrate solution is added to the microwells and allowed to incubate. If a sample contains anti-HAV IgM, the bound enzyme (HRP) causes the colorless TB in the Chromogen solution to change to blue. The blue color turns yellow after the addition of a Stopping Solution. If a sample does not contain anti-HAv IgM, the Chromogen / Substrate solution in the well remains colorless during the substrate incubation, and after the addition of the Stopping Solution. The color intensity is measured spectrophotometrically. Absorbance value readings for patient specimens are compared to the cutoff value.

# BIO RAD

# KIT COMPONENTS

<table><tr><td colspan="1" rowspan="1">Component</td><td colspan="1" rowspan="1">Description</td></tr><tr><td colspan="1" rowspan="1">R1 Microwell Strip Plates</td><td colspan="1" rowspan="1">Two (2) x 12 strips of 8 wells coated with polyclonal anti-human IgMantibodies.</td></tr><tr><td colspan="1" rowspan="1">R2 Wash SolutionConcentrate (30x)</td><td colspan="1" rowspan="1">One (1) 120 mL bottle, Tris buffer containing NaCl and Tween 20.</td></tr><tr><td colspan="1" rowspan="1">CO Negative Control</td><td colspan="1" rowspan="1">One (1) 1 mL vial, containing human plasma, negative for IgM anti-HAV antibodies, total anti-HAV antibodies, HBs antigen, anti-HCVantibodies and anti-HIV-1/HIV-2 antibodies. Preservatives: Sodiumazide (&lt; 0.1%) and Proclin™m 300 (0.25%).</td></tr><tr><td colspan="1" rowspan="1">C1 Positive Control</td><td colspan="1" rowspan="1">One (1) 1 mL vial, containing human plasma, positive for IgM anti-HAVantibodies and negative for HBs antigen, anti-HCV antibodies and anti-HIV-1/HIV-2 antibodies, diluted in human plasma pool negative foranti-HAV antibodies. Preservatives : Sodium azide (&lt; 0.1%) andProclin™M300 (0.25%).</td></tr><tr><td colspan="1" rowspan="1">C2 Calibrator</td><td colspan="1" rowspan="1">One (1) 1.6 mL vial, containing human plasma, positive for IgM anti-HAV antibodies and negative for HBs antigen, anti-HCV antibodies andanti anti-HIV-1/HIV-2 antibodies, diluted in colored synthetic base.Preservatives: Sodium azide (&lt; 0.1%) and Proclin™ 300 (0.25%).</td></tr><tr><td colspan="1" rowspan="1">R6 Sample Diluent</td><td colspan="1" rowspan="1">Two (2) x 14 mL bottles, Tris buffer containing protein and sampleindicator dye. Preservative: Proclin™ 300 (0.1%).</td></tr><tr><td colspan="1" rowspan="1">R7a HAV Viral Antigen</td><td colspan="1" rowspan="1">One (1) 13 mL bottle, Inactivated HAV virus in Tris buffer containingproteins and sample indicator dye. Preservative: Proclin™ 300 (0.1%).</td></tr><tr><td colspan="1" rowspan="1">R7b Conjugate</td><td colspan="1" rowspan="1">One (1) 13 mL. bottle, Conjugate (peroxidase labeled mousemonoclonal antibody to HAV) in Tris buffer containing proteins,detergent, and sample indicator dye. Preservative: Proclin™ 300(0.1%).</td></tr><tr><td colspan="1" rowspan="1">R8 Substrate Buffer</td><td colspan="1" rowspan="1">One (1) 120 mL bottle, containing Hydogen Peroxide, citric acid /sodium acetate buffer and Dimethylsulfoxide (DMSO).</td></tr><tr><td colspan="1" rowspan="1">R9 Chromogen (11x)</td><td colspan="1" rowspan="1">One (1) 12 mL bottle, Solution containing Tetramethylbenzidine (TMB).</td></tr><tr><td colspan="1" rowspan="1">R10 Stopping Solution</td><td colspan="1" rowspan="1">One (1) 120 mL bottle, 1 N H2SO4.</td></tr><tr><td>Plate sealers</td><td>Eight (8) clear plastic sealers.</td></tr></table>

# INTENDED USE

The MONOLISA™ Anti-HAV IgM EIA is an in vitro enzyme immunoassay kit intended for use in the qualitative detectionof IgM antibodies toHepatitis A virus (anti-HAV IgM) inhuman (adult and pediatric) serum or plasma (EDTA, Heparin, Citrate, ACD).

This assay is not intended fr screening blood or solid or soft tissue donors.

# INDICATIONS FOR USE

The MONOLISA™ Anti-HAV IgM EIA kit is indicated for testing specimens from individuals who have signs and symptoms consistent with acute Hepatitis. Assay results, in conjunction with other serological or clinical information, may be used for the laboratory diagnosis of individuals with acute or recent Hepatitis A.

Assay performance characteristics have not been established for immunocompromised or immunosuppressed patients, and core blood or neonatal specimens.

# TECHNOLOGICAL CHARACTERISTICS

The following tables summarize similarities and differences between the MONOLISA™ Anti-HAV IgM EIA kit and the predicate device ETI-HA-IGMK PLUS.

Table 1: Similarities between kit components and materials   
Table 2: Differences between kit components and materials   

<table><tr><td colspan="1" rowspan="1">Similarities inComponents / Materials</td><td colspan="1" rowspan="1">MONOLISA™ Anti-HAVIgM EIACatalog# 72495</td><td colspan="1" rowspan="1">ETI-HA-IGMK PLUSCatalog# P001925</td></tr><tr><td colspan="1" rowspan="1">Conjugate</td><td colspan="1" rowspan="1">Peroxidase-labeled mousemonoclonal antibody to HAV.</td><td colspan="1" rowspan="1">Peroxidase-labeled mousemonoclonal antibody to HAV.</td></tr><tr><td colspan="1" rowspan="1">Positive Control</td><td colspan="1" rowspan="1">Human plasma, positive forIgM anti-HAV antibodies,diluted in human plasmanegative for anti-HAVantibodies.</td><td colspan="1" rowspan="1">Human serum/plasmareactive for IgM anti-HAV,diluted with buffer.</td></tr><tr><td colspan="1" rowspan="1">Chromogen</td><td colspan="1" rowspan="1">Tetramethybenzidine (TMB)</td><td colspan="1" rowspan="1">Tetramethylbenzidine (TMB)</td></tr><tr><td colspan="1" rowspan="1">Substrate</td><td colspan="1" rowspan="1">Hydrogen Peroxide</td><td colspan="1" rowspan="1">Hydrogen Peroxide</td></tr><tr><td colspan="1" rowspan="1">Washing Solution</td><td colspan="1" rowspan="1">Concentrated buffered solutionwith Tween 20.</td><td colspan="1" rowspan="1">Concentrated buffered solutionwith detergents.</td></tr><tr><td colspan="1" rowspan="1">Sample diluent</td><td colspan="1" rowspan="1">Buffered solution with proteinsand sample indicator dye.</td><td colspan="1" rowspan="1">Buffered solution withproteins and an inert bluedye.</td></tr><tr><td colspan="1" rowspan="1">Differences inComponents / Materials</td><td colspan="1" rowspan="1">MONOLISA™ Anti-HAVIgM EIACatalog# 72495</td><td colspan="1" rowspan="1">ETI-HA-IGMK PLUSCatalog# P001925</td></tr><tr><td colspan="1" rowspan="1">Solid Phase</td><td colspan="1" rowspan="1">Microplate wells coated withpolyclonal anti-human IgMantibodies.</td><td colspan="1" rowspan="1">Microplate wells coated withmouse monoclonal antibodiesto human IgM.</td></tr><tr><td colspan="1" rowspan="1">Negative Control</td><td colspan="1" rowspan="1">Human plasma, negative forIgM anti-HAV antibodies andtotal anti-HAV antibodies.</td><td colspan="1" rowspan="1">Human serum/plasma non-reactive for IgM anti-HAV andreactive for IgG anti-HAV,diluted in buffer.</td></tr><tr><td colspan="1" rowspan="1">Calibrator</td><td colspan="1" rowspan="1">Human plasma, positive forIgM anti-HAV antibodiesdiluted in buffer.</td><td colspan="1" rowspan="1">Human serum/plasma non-reactive for IgM anti-HAV andreactive for IgG anti-HAVdiluted with buffer.</td></tr><tr><td colspan="1" rowspan="1">Conjugate</td><td colspan="1" rowspan="1">Ready-to-use</td><td colspan="1" rowspan="1">To be diluted.</td></tr><tr><td colspan="1" rowspan="1">Stopping Solution</td><td colspan="1" rowspan="1">1N H2SO4.</td><td colspan="1" rowspan="1">0.4N H2SO4.</td></tr><tr><td colspan="1" rowspan="1">Required sample volume</td><td colspan="1" rowspan="1">20 μl</td><td colspan="1" rowspan="1">10 μl</td></tr></table>

Table 3: Similarities between kits with regard to function and use   

<table><tr><td rowspan=1 colspan=1>Similarities in Functionand Use</td><td rowspan=1 colspan=1>MONOLISA™ Anti-HAVIgM EIACatalog# 72495</td><td rowspan=1 colspan=1>ETI-HA-IGMK PLUSCatalog# P001925</td></tr><tr><td rowspan=1 colspan=1>Test Method</td><td rowspan=1 colspan=1>EIA (antibody capture)</td><td rowspan=1 colspan=1>EIA (antibody capture)</td></tr><tr><td rowspan=1 colspan=1>Specimen StorageRequirements</td><td rowspan=1 colspan=1>Samples may be stored at 2-8°C for up to 24 hours.</td><td rowspan=1 colspan=1>Samples may be stored at 2-8°C for up to 24 hours.</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>96-well microplate</td><td rowspan=1 colspan=1>96-well microplate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Assay for the qualitativedetection of anti-HAV IgMantibodies in human serum orplasma.</td><td rowspan=1 colspan=1>Assay for the qualitativedetection of anti-HAV IgMantibodies in human serum orplasma.</td></tr><tr><td rowspan=1 colspan=1>Wavelength</td><td rowspan=1 colspan=1>Dual wavelength reading at450 nm and 615/630 nm.</td><td rowspan=1 colspan=1>Dual wavelength reading at450 nm and 630 nm.</td></tr><tr><td rowspan=1 colspan=1>Interpretation of results</td><td rowspan=1 colspan=1>Obtained absorbancereadings for patientspecimens compared to cut-off value determined by themean of the calibratorabsorbance values.</td><td rowspan=1 colspan=1>Obtained absorbancereadings for patient samplescompared to cut-off valuedetermined by the mean ofthe calibrator absorbancevalues.</td></tr></table>

Table 4: Differences between kits with regard to function and use   

<table><tr><td rowspan=1 colspan=1>Differences in Functionand Use</td><td rowspan=1 colspan=1>MONOLISA™ Anti-HAVIgM EIACatalog# 72495</td><td rowspan=1 colspan=1>ETI-HA-IGMK PLUSCatalog# P001925</td></tr><tr><td rowspan=1 colspan=1>SpectrophotometricVerification of Sample andReagent Pipeting</td><td rowspan=1 colspan=1>Possible (but optional)</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Cutoff calculation</td><td rowspan=1 colspan=1>Mean absorbance ofcalibrator values divided by 4</td><td rowspan=1 colspan=1>Mean absorbance of thecalibrator values + 0.250</td></tr></table>

# EXPECTED VALUES

# Healthy individuals

The expected results of the MONOLISA™ Anti-HAV IgM EIA assay were determined in presumably healthy individuals from the Mid-west US (St Louis, Missouri), the Western US (California and Washington) and from Europe (Parma, Italy).

In the Mid -west, the population was 55% female and 45% male, with ages that ranged from 1 to 96 years. $48 \%$ (134) were pediatric specimens.

The majority o the subjects wee White/Caucasian $( 6 4 \% )$ ,and $32 \%$ were black or African American; for $4 \%$ data were not available.

In the Western USA, 73% were from California and 27% were from Washington. The population was $56 \%$ female and $44 \%$ male, with ages that ranged from 15 to 90 years.

In Europe, the population was $50 \%$ female and $50 \%$ male, with ages that ranged from 18 to 87 years.

are presented below (Tables 5, 6 and).

The percent of Anti-HAV IgM reactive results with MONOLISA™ Anti-HAV IgM EIA were 0.4% for both Mid-west and Western US and $0 . 7 \%$ in Europe.

Table 5: Expected Results for MONOLISA™ Anti-HAV IgM EIA in subjects rom the MidWest US (N= 280)   

<table><tr><td colspan="9">MONOLISATM Anti-HAV IgM EIA</td></tr><tr><td rowspan="2">Age Range</td><td rowspan="2">Gender</td><td colspan="2">Reactive</td><td colspan="2">Borderline</td><td colspan="2">Nonreactive</td><td rowspan="2">Total</td></tr><tr><td>N</td><td>%</td><td>N</td><td>%</td><td>N</td><td>%</td></tr><tr><td>&lt; 10</td><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>35</td><td>100.0%</td><td>35</td></tr><tr><td rowspan="3">10 -19</td><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>38</td><td>100.0%</td><td>38</td></tr><tr><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>38</td><td>100.0%</td><td>38</td></tr><tr><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>23</td><td>100.0%</td><td>23</td></tr><tr><td rowspan="2">20-29</td><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>5</td><td>100.0%</td><td>5</td></tr><tr><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>3</td><td>100.0%</td><td>3</td></tr><tr><td rowspan="2">30 -39</td><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>10</td><td>100.0%</td><td>10</td></tr><tr><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>9</td><td>100.0%</td><td>9</td></tr><tr><td rowspan="2">40 -49</td><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>13</td><td>100.0%</td><td>13</td></tr><tr><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>8</td><td>100.0%</td><td>8</td></tr><tr><td rowspan="2">50 -59</td><td>Female</td><td>1</td><td>5.6%</td><td>1</td><td>5.6%</td><td>16</td><td>88.9%</td><td>18</td></tr><tr><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>17</td><td>100.0%</td><td>17</td></tr><tr><td rowspan="2">60 -69</td><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>14</td><td>100.0%</td><td>14</td></tr><tr><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>13</td><td>100.0%</td><td>13</td></tr><tr><td rowspan="2">70-79</td><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>9</td><td>100.0%</td><td>9</td></tr><tr><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>6</td><td>100.0%</td><td>6</td></tr><tr><td rowspan="2">80-89</td><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>13</td><td>100.0%</td><td>13</td></tr><tr><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>6</td><td>100.0%</td><td>6</td></tr><tr><td rowspan="2">&gt;=90</td><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>0</td></tr><tr><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>2</td><td>100.0%</td><td>2</td></tr><tr><td colspan="2">Total</td><td>1*</td><td>0.4%</td><td>1**</td><td>0.4%</td><td>278</td><td>99.3%</td><td>280</td></tr></table>

\*1 subject was reactive with a result of 2.25 $( { \mathsf { S } } / { \mathsf { C O } } )$ \*\* 1 subject gave an initial borderline result of 1.04 (S/CO).

Tab : Ep Result or OLIS™AntiHAV IM EIA i je Western US (N= 245)   

<table><tr><td colspan="9">MONOLISA™ Anti-HAV IgM EIA</td></tr><tr><td rowspan="2">Age Range</td><td rowspan="2">Gender</td><td colspan="2">Reactive</td><td colspan="2">Borderline</td><td colspan="2">Nonreactive</td><td rowspan="2">Total</td></tr><tr><td>N</td><td>%</td><td>N</td><td>%</td><td>N</td><td>%</td></tr><tr><td>&lt;19</td><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>5</td><td>100.0%</td><td>5</td></tr><tr><td></td><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>5</td><td>100.0%</td><td>5</td></tr><tr><td rowspan="2">20- 29</td><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>26</td><td>100.0%</td><td>26</td></tr><tr><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>24</td><td>100.0%</td><td>24</td></tr><tr><td rowspan="2">30 -39</td><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>20</td><td>100.0%</td><td>20</td></tr><tr><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>18</td><td>100.0%</td><td>18</td></tr><tr><td rowspan="2">40 -49</td><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>18</td><td>100.0%</td><td>18</td></tr><tr><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>22</td><td>100.0%</td><td>22</td></tr><tr><td rowspan="2">50 -59</td><td>Female</td><td>1</td><td>2.6%</td><td>0</td><td>N/A</td><td>38</td><td>97.4%</td><td>39</td></tr><tr><td>Male</td><td>0</td><td>N/A</td><td>1</td><td>4.8%</td><td>20</td><td>95.2%</td><td></td></tr><tr><td rowspan="2">60 -69</td><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>12</td><td>100.0%</td><td>21</td></tr><tr><td>Male</td><td>0</td><td>N/A</td><td>: 0</td><td>N/A</td><td></td><td></td><td>12</td></tr><tr><td rowspan="3">70-79 80-89</td><td>Female</td><td>0</td><td>N/A</td><td></td><td></td><td>12</td><td>100.0%</td><td>12</td></tr><tr><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>9</td><td>100.0%</td><td>9</td></tr><tr><td>Female</td><td>0</td><td>N/A</td><td>0 0</td><td>N/A</td><td>2</td><td>100.0%</td><td>2</td></tr><tr><td>&gt;=90</td><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A N/A</td><td>6 4</td><td>100.0% 100.0%</td><td>6 4</td></tr><tr><td rowspan="2"></td><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>1</td><td>100.0%</td><td>1</td></tr><tr><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>0</td></tr><tr><td>Unknown</td><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>1</td><td>100.0%</td><td>1</td></tr><tr><td colspan="2">Total</td><td>1*</td><td>0.4%</td><td>1**</td><td>0.4%</td><td>243</td><td>99.2%</td><td>245</td></tr></table>

\*1 subject was reactive with a result of 1.34 (S/CO) $( { \mathsf S } / { \mathsf C } { \mathsf 0 } )$ .

Table 7: Expectd Results for MONOLISA™Anti-HAV IgM EIA in subjects from Italy, Europe (N= 285)   

<table><tr><td colspan="9">MONOLISA™ Anti-HAV IgM EIA</td></tr><tr><td rowspan="2">Age Range</td><td rowspan="2">Gender</td><td colspan="2">Reactive</td><td colspan="2">Borderline</td><td colspan="2">Nonreactive</td><td rowspan="2">Total</td></tr><tr><td>N</td><td>%</td><td>N</td><td>%</td><td>N</td><td>%</td></tr><tr><td>&lt; 19</td><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>1</td><td>100.0%</td><td>1</td></tr><tr><td>20- 29</td><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>1</td><td>100.0%</td><td>1</td></tr><tr><td rowspan="3">30 -39</td><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>3</td><td>100.0%</td><td>3</td></tr><tr><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>2</td><td>100.0%</td><td>2</td></tr><tr><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>7</td><td>100.0%</td><td>7</td></tr><tr><td rowspan="2">40 -49</td><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>7</td><td>100.0%</td><td>7</td></tr><tr><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>21</td><td>100.0%</td><td>21</td></tr><tr><td rowspan="2">50 -59</td><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>19</td><td>100.0%</td><td>19</td></tr><tr><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>22</td><td>100.0%</td><td>22</td></tr><tr><td rowspan="2">60 -69</td><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>27</td><td>100.0%</td><td>27</td></tr><tr><td>Female</td><td>1</td><td>2.5%</td><td>1</td><td>2.5%</td><td>41</td><td>95.0%</td><td>43</td></tr><tr><td></td><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>27</td><td>100.0%</td><td>27</td></tr><tr><td rowspan="2">70-79</td><td>Female</td><td>1</td><td>3.6%</td><td>0</td><td>N/A</td><td>31</td><td>96.4%</td><td>32</td></tr><tr><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>37</td><td>100%</td><td>37</td></tr><tr><td rowspan="2">80-89</td><td>Female</td><td>0</td><td>N/A</td><td>0</td><td>N/A</td><td>13</td><td>100%</td><td>13</td></tr><tr><td>Male</td><td>0</td><td>N/A</td><td>0</td><td>N/A “</td><td>23</td><td>100%</td><td>23</td></tr><tr><td colspan="2">Total</td><td>2*</td><td>0.7%</td><td>1**</td><td>0.4%</td><td>282</td><td>98.9%</td><td>285</td></tr></table>

\*2 subjects gave reactive results of 3.4 and 1.2 $( { \mathsf { S } } / { \mathsf { C O } } )$ $\ast \ast _ { 1 }$ $( { \mathsf { S } } / { \mathsf { C O } } )$

# Adult Subjects at High Risk for Viral Hepatitis:

Expected results of asymptomatic prospective high-risk subjects determined from a multi-center study in the US and in Europe are reported in the following tables.

A total of 230 Us Subjects were at high risk for viral hepatitis including intravenous drug users $( N =$ 55), homosexual males $( N = 1 5 )$ , sex workers $( N = 3 9 )$ , prison history $( N = 9 2 )$ , high-risk sex partners $( N = 2 5 )$ , high-risk occupation/health care workers $( N = 4 )$ . Many had more than 1 high-risk behavior or risk factor. Subjects were from Los Angeles, CA, $( 8 6 . 5 \% )$ , Santa Ana, CA $( 4 . 3 \% ) ,$ or Miami, FL $( 9 . 1 \% )$ . The group was Caucasian $( 7 . 4 \% ) .$ , Black or African American $( 7 4 . 3 \% )$ , Hispanic or Latino $( 1 5 . 2 \% )$ , Asian $\left( 0 . 4 \% \right)$ , Native Hawaian or other Pacific Islander $\left( 0 . 4 \% \right)$ , and American Indian or Alaska native $( 0 . 9 \% ) _ { i }$ , with the remaining $1 . 3 \%$ represented by multiple ethnic groups.

The subjects were $81 \%$ male and $1 9 \%$ fle, o0  e of 45). The data are reported in Table 8.

T A V asymptomatic population was $0 \%$ .

The European group $( N = 6 2 )$ was $8 7 \%$ male and $13 \%$ female and ranged in age from 21 to 75 years (mean age of 40). It consisted of intravenous drug users (30), subjects who had clotting factor disorders (7) and MSM patients (25). The data are reported in Table 9.

T nHAV  u iLAVAhi asymptomatic population was $0 \%$ .

# BIO RAD

Table 8: Expected results for MONOLISA™ Anti-HAV IgM EIA in the US High risk Group for Viral Hepatitis A $( N = 2 3 0 )$   

<table><tr><td rowspan=1 colspan=9>MONOLISAT Anti-HAV IgM EIA</td></tr><tr><td rowspan=2 colspan=1>AgeRange</td><td rowspan=2 colspan=1>Gender</td><td rowspan=1 colspan=2>Reactive</td><td rowspan=1 colspan=2>Borderline</td><td rowspan=1 colspan=2>Nonreactive</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td></tr><tr><td rowspan=1 colspan=1>&lt; 19</td><td rowspan=1 colspan=1>FemaleMale</td><td rowspan=1 colspan=1>0:    0</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>100.0%100.0%</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>20- 29</td><td rowspan=1 colspan=1>FemaleMale</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>100.0%100.0%</td><td rowspan=1 colspan=1>32</td></tr><tr><td rowspan=1 colspan=1>30 -39</td><td rowspan=1 colspan=1>FemaleMale</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>736</td><td rowspan=1 colspan=1>100.0%100.0%</td><td rowspan=1 colspan=1>736</td></tr><tr><td rowspan=1 colspan=1>40 -49</td><td rowspan=1 colspan=1>FemaleMale</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>01</td><td rowspan=1 colspan=1>N/A1.2 %</td><td rowspan=1 colspan=1>2484</td><td rowspan=1 colspan=1>100.0%98.8%</td><td rowspan=1 colspan=1>2485</td></tr><tr><td rowspan=1 colspan=1>50 -59</td><td rowspan=1 colspan=1>Female  ..Male</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>751</td><td rowspan=1 colspan=1>100.0%100.0%</td><td rowspan=1 colspan=1>751</td></tr><tr><td rowspan=1 colspan=1>60 -69</td><td rowspan=1 colspan=1>FemaleMale</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>100.0%100.0%</td><td rowspan=1 colspan=1>110</td></tr><tr><td rowspan=1 colspan=1>70-79</td><td rowspan=1 colspan=1>FemaleMale</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>02</td><td rowspan=1 colspan=1>N/A100.0%</td><td rowspan=1 colspan=1>02</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.4%</td><td rowspan=1 colspan=1>229</td><td rowspan=1 colspan=1>99.6%</td><td rowspan=1 colspan=1>230</td></tr></table>

Table : Expected results for MONOLISA™ Anti-HAV IgM EIA in the European Hih risk group for Viral Hepatitis A $( N { \pmb { \imath } } = 6 2 )$   

<table><tr><td rowspan=1 colspan=9>MONOLISA™ Anti-HAV IgM EIA</td></tr><tr><td rowspan=2 colspan=1>AgeRange</td><td rowspan=2 colspan=1>Gender</td><td rowspan=1 colspan=2>Reactive</td><td rowspan=1 colspan=2>Borderline</td><td rowspan=1 colspan=2>Non reactive</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%/</td></tr><tr><td rowspan=1 colspan=1>&lt; 19</td><td rowspan=1 colspan=1>FemaleMale</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>00</td></tr><tr><td rowspan=1 colspan=1>20- 29</td><td rowspan=1 colspan=1>FemaleMale</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>511</td><td rowspan=1 colspan=1>100.0%100.0%</td><td rowspan=1 colspan=1>511</td></tr><tr><td rowspan=1 colspan=1>30 -39</td><td rowspan=1 colspan=1>FemaleMale</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>214</td><td rowspan=1 colspan=1>100.0%100.0%</td><td rowspan=1 colspan=1>214</td></tr><tr><td rowspan=1 colspan=1>40 -49</td><td rowspan=1 colspan=1>FemaleMale</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>114</td><td rowspan=1 colspan=1>100.0%100.0%</td><td rowspan=1 colspan=1>114</td></tr><tr><td rowspan=1 colspan=1>50 -59</td><td rowspan=1 colspan=1>FemaleMale</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>011</td><td rowspan=1 colspan=1>N/A100.0%</td><td rowspan=1 colspan=1>011</td></tr><tr><td rowspan=1 colspan=1>60 -69</td><td rowspan=1 colspan=1>FemaleMale</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>02</td><td rowspan=1 colspan=1>N/A100.0%</td><td rowspan=1 colspan=1>02</td></tr><tr><td rowspan=1 colspan=1>70-79:</td><td rowspan=1 colspan=1>FemaleMale</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>02</td><td rowspan=1 colspan=1>N/A100.0%</td><td rowspan=1 colspan=1>02</td></tr><tr><td rowspan=1 colspan=1>&gt;80</td><td rowspan=1 colspan=1>FemaleMale</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>N/AN/A</td><td rowspan=1 colspan=1>00</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>62</td></tr></table>

# PERFORMANCE CHARACTERISTICS

# Clinical Performance

A multi-center prospective and retrospective study was conducted to evaluate the clinical hLA A   y il symptoms and those at high risk for Hepatitis infection. Specimens were collected in 3 different graphical ars  ees we collece  n  we collec (France and Italy).

The US population consisted of 174 subjects with signs and symptoms of Hepatitis. In this group, 60% were male and 40% were female, and they ranged in age from 17 to 72 years (mean age of . The group was Caucasian $( 1 3 . 2 \% )$ ,Black or African American $( 4 . 6 \% )$ ,Hispanic or Latino $( 2 . 9 \% )$ , and Asian $( 4 1 . 9 \% ) ,$ with the remaining $1 . 1 \%$ represented by multiple ethnic groups. The ethnicity of $3 6 . 8 \%$ was unknown. Among these subjects, 23 $( 1 3 . 2 \% )$ were pediatric samples.

The 230 subjects from the high-risk group for Hepatitis A include intravenous drug users (N= 55), homosexual males $( N = 1 5 )$ , sex workers $( N = 3 9 )$ , prison history $( N = 9 2 )$ ,high-risk sex partners $( N = 2 5 )$ , high-risk occupation/health care workers $( N = 4 )$ . Many had more than 1 high-risk behavior o risk factor.The group was Caucasian $( 7 . 4 \% )$ ,Black orAfrican American $( 7 4 . 3 \% )$ Hispanic or Latino $( 1 5 . 2 \% )$ ,Asian $\left( 0 . 4 \% \right) .$ ,Native Hawaiian" or other Pacific Islander $\left( 0 . 4 \% \right) _ { i }$ and American Indian or Alaska native $\left( 0 . 9 \% \right) _ { i }$ with the remaining $1 . 3 \%$ represented by multiple ethnic groups. In this group, $8 1 \%$ were male and $1 9 \%$ were female, and they ranged in age from 18 to 70 years (mean age of 45). Among these 230 subjects, 2 $( 0 . 9 \% )$ were pediatric samples.

The European population consisted of 253 specimens collected from patients with signs and symptoms of Hepatitis. In this group, $5 1 \%$ were male and $49 \%$ were female and they ranged in age from 1 to 105 years (mean age of 53).

Sixty-two (62) specimens were collected from a population at high risk for hepatitis composed of intravenous drug users (30), subjects who had clottig factordisorders (7) and MSM patints (25). The group was $8 7 \%$ male and $1 3 \%$ female and ranged in age from 21 to 75 years (mean age of 40).

There were 345 specimens from an asymptomatic hospitalized population and 34 were from healthcare workers (for HAV pre-vaccination screening).

One hundred and fifty one (151) patients had recovered HAV infection.

Among these 845 european samples, 36 $( 4 . 3 \% )$ were from pediatric subjects

Percent Agreement

The u tai wih L™ntiHAV EA wee cd with he results using the comparative assay.

The positive and negative percent agreements and the $9 5 \%$ exact confidence between MLISA Anti-HAV IM EIA and the coparative assay wee calculat.

eei  pern eentrdersultheollow we

Specimens that were borderline with the comparative assay and reactive with MoNoLSA™ AV  IA     i  OLAV  I Specimens that were borderline with the comparative assay and non reactive with MoNOLISA™ Anti-HAV IgM EIA were considered as false negatives for MONOLISA™ Anti-HAV IgM EIA

The results obtained with the US specimens and with the European specimens are presented in the following tables:

Table 10: MONOLISA™M Anti-HAV IgM EIA versus the comparative assay results in the US population $( N = 4 0 4 )$ EY   

<table><tr><td rowspan=3 colspan=1>Subjectcategory</td><td rowspan=1 colspan=3>Comparative assay:Positive</td><td rowspan=1 colspan=3>Comparative assay :Borderline</td><td rowspan=1 colspan=3>Comparative assay:Negative</td><td rowspan=3 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=3>MONOLISA™M Anti-HAV IgM EIA</td><td rowspan=1 colspan=3>MONOLISA™M Anti-HAV IgM EIA</td><td rowspan=1 colspan=3>MONOLISATM Anti-HAV IgM EIA</td></tr><tr><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>BRD</td><td rowspan=1 colspan=1>NR</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>BRD</td><td rowspan=1 colspan=1>NR</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>BRD</td><td rowspan=1 colspan=1>NR</td></tr><tr><td rowspan=1 colspan=1>Subjects withsigns andsymptoms</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>171</td><td rowspan=1 colspan=1>174</td></tr><tr><td rowspan=1 colspan=1>Subjects withhigh risk forHepatitis</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>229</td><td rowspan=1 colspan=1>230</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2b</td><td rowspan=1 colspan=1>1ab</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>404</td></tr></table>

Reactive, NR: Nonreactive, BRD: Borderline e pl wihA s cnsde s le hee samples were found HAV IgG reactive.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Positive percentagreement</td><td rowspan=1 colspan=1>95% ExactConfidence interval</td><td rowspan=1 colspan=1>Negative percentagreement</td><td rowspan=1 colspan=1>95% ExactConfidence interval</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>100%(1/1)</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>99.3%(400/403)</td><td rowspan=1 colspan=1>97.8- 99.9%</td></tr></table>

Table 11: MONOLISATM Anti-HAV IgM EIA versus the comparative assay results in the European population $( N = 8 4 5 )$   

<table><tr><td colspan="1" rowspan="3">Subjectcaategory</td><td colspan="3" rowspan="1">Comparativeassay: Positive</td><td colspan="3" rowspan="1">Comparativeassay: Borderline</td><td colspan="3" rowspan="1">Comparativeassay: Negative</td><td colspan="1" rowspan="3">Total</td></tr><tr><td colspan="3" rowspan="1">MONOLISA™MAnti-HAV IgMEIA</td><td colspan="3" rowspan="1">MONOLISA™MAnti-HAV IgMEIA</td><td colspan="3" rowspan="1">MONOLISATMAnti-HAV IgMEIA</td></tr><tr><td colspan="1" rowspan="1">R</td><td colspan="1" rowspan="1">BRD</td><td colspan="1" rowspan="1">NR</td><td colspan="1" rowspan="1">R</td><td colspan="1" rowspan="1">BRD</td><td colspan="1" rowspan="1">NR</td><td colspan="1" rowspan="1">R</td><td colspan="1" rowspan="1">BRD</td><td colspan="1" rowspan="1">NR</td></tr><tr><td colspan="1" rowspan="1">Generalhospitalizedpopulation</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1b</td><td colspan="1" rowspan="1">342</td><td colspan="1" rowspan="1">345</td></tr><tr><td colspan="1" rowspan="1">Sign/Symptoms ofHepatitis</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">250</td><td colspan="1" rowspan="1">253</td></tr><tr><td colspan="1" rowspan="1">Subjects withhigh risk forHepatitis</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">62</td><td colspan="1" rowspan="1">62</td></tr><tr><td colspan="1" rowspan="1">Healthcareworkers</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">34</td><td colspan="1" rowspan="1">34</td></tr><tr><td colspan="1" rowspan="1">Infected/recovered HAV</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">2a</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">148</td><td colspan="1" rowspan="1">151</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">2c</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">5c</td><td colspan="1" rowspan="1">1c</td><td colspan="1" rowspan="1">836</td><td colspan="1" rowspan="1">845</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Positive percentagreement</td><td rowspan=1 colspan=1>95% ExactConfidence interval</td><td rowspan=1 colspan=1>Negative percentagreement</td><td rowspan=1 colspan=1>95% ExactConfidence interval</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>100%(1/1)</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>99.0%(836/844)</td><td rowspan=1 colspan=1>98.1-99.6</td></tr></table>

R: Reactive, NR: Nonreactive, BRD : Borderline the 2 borderline samples with the comparative assay were considered "false positive" with MoNOLISA bordeine sample with MooA was conside s "alse posive hee samples were found HAV IgG Reactive

# Acute HAV Infection:

Among the retrospective samples, 84 were from subjects with a medical history and laboratory results indicative of acute Hepatitis A. The subjects included 56% male, 37% female; the gender was not available for $7 \%$ .The mean age was 21, and subjects ranged from 1 to 55 years. Among them 39 were pediatric subjects.

The results are presented in the following table:

Table 12 : Comparison of Results for MONOLISA™M Anti-HAV IgM EIA versus the comparative assay on Acute HAv infection in the adult and pediatric European Population $( N = 8 4 )$ :   

<table><tr><td></td><td colspan="3">Comparative assay: Positive</td><td colspan="3">Comparative assay: Borderline</td><td colspan="3">Comparative assay : Negative</td><td></td></tr><tr><td rowspan="2"></td><td colspan="3">MONOLISATM Anti- HAV IgM EIA</td><td colspan="3">MONOLISA™M Anti- HAV IgM EIA</td><td colspan="3">MONOLISA™ Anti- HAV IgM EIA</td><td rowspan="2">total</td></tr><tr><td>R</td><td>BRD</td><td>NR</td><td>R</td><td>BRD</td><td>NR</td><td>R</td><td>BRD</td><td>NR</td></tr><tr><td>Adults</td><td>45</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>45</td></tr><tr><td>Pediatrics</td><td>39</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>39</td></tr><tr><td>Total</td><td>84</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>84</td></tr></table>

RReactive, NR: Nonreactive, BRD : Borderline

The positive agreement was $100 \%$ (84/84) with a $9 5 \%$ exact confidence interval of $9 6 . 5 \%$ to EY $100 \%$ .

# Performance of MONOLISA ™ Anti-HAV EIA in Pediatric subjects:

Sy- pediati mples we estdurg he US n Eurpean ciicl sudi ti to the 39 samples from acute HAV infection.

Among the US population, 23 had signs and symptoms of hepatitis and 2 were from the high risk group. In the European population, 3 belonged tohe general hospitalized population,  had sns and symptoms of hepatitis, 2 were from the high risk group, 3 were healthcare workers, 5 had recovered from Hepatitis A infection. The results from these pediatric samples are summarized in the following table.

Table 13 : Comparison of Results for MONOLISA™M Anti-HAV IgM EIA versus the comparative assay in the Pediatric European and Us Population $( N = 6 1 )$   

<table><tr><td rowspan=2 colspan=1>Subjectcategory</td><td rowspan=1 colspan=3>Comparative assay:Positive</td><td rowspan=1 colspan=3>Comparative assay:Borderline</td><td rowspan=1 colspan=3>Comparative assay :Negative</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=3>MONOLISA™M Anti-HAV IgM EIAR    BRD     NR</td><td rowspan=1 colspan=3>MONOLISA™M Anti-HAV IgM EIAR    BRD    NR</td><td rowspan=1 colspan=3>MONOLISA™ Anti-HAV IgM EIAR    BRD    NR</td></tr><tr><td rowspan=1 colspan=1>Europeanpediatrics</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>36</td></tr><tr><td rowspan=1 colspan=1>USpediatrics</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2$</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>61</td></tr></table>

R: Reactive, NR: Nonreactive, BRD : Borderline these samples were found HAV IgG Reactive

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Positive percentagreement</td><td rowspan=1 colspan=1>95% ExactConfidence interval</td><td rowspan=1 colspan=1>Negative percentagreement</td><td rowspan=1 colspan=1>95% ExactConfidence interval</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>96.7%(59/61)</td><td rowspan=1 colspan=1>88.6 - 99.6</td></tr></table>

Including the combined US and European Sites, the positive percent agreement of the MoNOLISA™M Anti-HAV IgM EIA with the comparative assay was $100 \%$ (86/86), with a $9 5 \%$ exact confidence interval of $9 6 . 6 \%$ to $100 \%$ .The negative percent agreement of the MONOLISA™ Anti-HAV IgM EIA with the comparative assay was $9 9 . 1 \%$ (1233/1244) with a $9 5 \%$ exact confidence interval of $9 8 . 4 \%$ to $9 9 . 6 \%$ .

# Seroconversion Panels

Eight commercially available HAV seroconversion panels were tested using MONOLISA™ Anti-HAV IgM EIA and the comparative assay to determine the sensitivity of the assay. The results are summarized in the following table:

Table 14: MONOLISA ™Anti-HAV IgM EIA Seroconversion panels Results   

<table><tr><td rowspan=1 colspan=1>Panel ID</td><td rowspan=1 colspan=1>MONOLISA™ Anti-HAV IgM EIA</td><td rowspan=1 colspan=1>Anti-HAV IgMComparative Assay</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Post bleed day of firstreactive result</td><td rowspan=1 colspan=1>Post bleed day of firstreactive result</td><td rowspan=1 colspan=1>Difference in Daysto Reactive result</td></tr><tr><td rowspan=1 colspan=1>07467A</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>60160K</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>60162K</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>HAV01</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>RP-004</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>RP-013</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>PHT901</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>PHT902</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>0</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Panel ID</td><td rowspan=1 colspan=1>MONOLISA™ Anti-HAVIgM EIA</td><td rowspan=1 colspan=1>Anti-HAV IgMComparative Assay</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Post bleed day of lastreactive result*</td><td rowspan=1 colspan=1>Post bleed day of lastreactive result*</td><td rowspan=1 colspan=1>Difference in Daysfrom last Reactiveresult</td></tr><tr><td rowspan=1 colspan=1>HAV01</td><td rowspan=1 colspan=1>91a$</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>+14</td></tr></table>

a: last bleed of the panel

For all seroconversion panels, both MONOLISA™ Anti-HAV IgM EIA and the comparative assay detected HAV IgM antibodies at the same first bleed. MONOLISA™ Anti-HAV IgM EIA appears to detect IgM for a longer period than the comparator assay for qualitative determination of IgM antibody to Hepatitis A.

Among seroconversion panels beginning with samples negative for anti-HAV antibodies and having subsequent samples to 5-6 months, one (PHT-902) becomes borderline after 5 months and one (HT-901) gives a negative result after more than 20months. Another seroconversion panel (RP013) with samples collected through 6 months has a declining ratio but still remains positive. The other panels contain members collected through 2 to 3 months.

# Cross Reactivity Study

The potential for cross reactivity to other disease states, or viruses was evaluated for the MONOLISA™ Anti-HAV IgM EIA Assay. In addition, samples containing rheumatoid factors, autoantibodies, anti-mouse antibodies were tested.

In total, 255 specimens (including both serum and plasma) from 16 groups of potential cross reactivity were tested. FDA approved methods were used to confirm the disease state of each specmen. Allthe samples were found negative on another commercially Anti-HAV IgM assay. The results are summarized in the following table:

Table 15: Potential cross reactivity study   

<table><tr><td>Clinical condition</td><td>Number tested</td><td>MONOLISATM Anti-HAV IgM EIA nonreactive</td></tr><tr><td>Hepatitis C (HCV) Hepatitis B (HBV) HBs Ag</td><td>15</td><td>15</td></tr><tr><td>Hepatitis B (HBV) anti HBc</td><td>15 15</td><td>15 15</td></tr><tr><td>Human Immunodeficiency Virus (HIV)</td><td>15</td><td>15</td></tr><tr><td>Epstein Barr Virus (EBV) IgG</td><td>15</td><td></td></tr><tr><td>Epstein Barr Virus (EBV) IgM</td><td>15</td><td>15</td></tr><tr><td>Cytomegalovirus (CMV) IgG</td><td>15</td><td>15 15</td></tr><tr><td>Cytomegalovirus (CMV) IgM</td><td>15</td><td>15</td></tr><tr><td>Rubella IgG</td><td>15</td><td>15</td></tr><tr><td>Toxoplasmosis IgG</td><td>15</td><td>15</td></tr><tr><td>Toxoplasmosis IgM</td><td>15</td><td></td></tr><tr><td>Mumps IgG</td><td>15</td><td>15</td></tr><tr><td>Varicella Zoster Virus(VZV) IgG</td><td></td><td>15</td></tr><tr><td>Varicella Zoster Virus(VZV) IgM</td><td>15</td><td>15</td></tr><tr><td>Anti Nuclear Antibody (ANA)</td><td>15</td><td>15</td></tr><tr><td>Human Anti Mouse Antibody (HAMA)</td><td>15</td><td>15</td></tr><tr><td></td><td>15</td><td>15</td></tr><tr><td>Rheumatoid Arthritis</td><td>15</td><td>15</td></tr><tr><td>Total Samples tested</td><td>255</td><td>255</td></tr></table>

All  55 speens were found noeacive with HAV IgM with MONOLSAAnti-HAV IgM and with the predicate assay.

# Precision Study

Within - Laboratory Precision Study

A 21-member panel was tested: serum samples with the 6 corresponding plasma samples (EDTA DT , SodiuCtra SodHeparn, Lithi hepar, ACDat different lev1 negative, 1 negative near the cutoff, 1 low positive near the cutoff) were tested on 1 lot, in duplicate, in 2 different runs per day (am and pm), by the same operator for a period of 20 days. The data were analyzed following the CLSI guidance EP5A2. The mean ratio, the Standard Deviation (SD) and percent coefficient of variation $( \% C V )$ were calculated for each panel member.

The data summary is shown in the following table:

Table 16: MONOLISA™M Anti-HAV IgM EIA Precision Results by Panel Member Signal to Cutoff (S/CO)   

<table><tr><td rowspan="2">Panel Member</td><td rowspan="2">N</td><td rowspan="2">Mean S/CO</td><td colspan="2">Within run1</td><td colspan="2">Between Run 2</td><td colspan="2">Between Day 3</td><td colspan="2">Total 4</td></tr><tr><td>SD</td><td>CV (%)</td><td>SD</td><td>CV (%)</td><td>SD</td><td>CV (%)</td><td>SD</td><td>CV (%)</td></tr><tr><td>Negative Control CO</td><td>40</td><td>0.08</td><td>NA</td><td>NA</td><td>0.01</td><td>11.0%</td><td>0.00</td><td>0.8%</td><td>0.01</td><td>11.0%</td></tr><tr><td>Positive Control C1</td><td>40</td><td>2.03</td><td>NA</td><td>NA</td><td>0.08</td><td>4.2%</td><td>0.05</td><td>2.5%</td><td>0.10</td><td>4.8%</td></tr><tr><td>serum 1</td><td>80</td><td>0.05</td><td>0.00</td><td>5.5%</td><td>0.01</td><td>14.1%</td><td>0.00</td><td>7.7%</td><td>0.01</td><td>17.0%</td></tr><tr><td>EDTA K2 1</td><td>80</td><td>0.05</td><td>0.00</td><td>6.3%</td><td>0.01</td><td>13.4%</td><td>0.00</td><td>6.4%</td><td>0.01</td><td>16.1%</td></tr><tr><td>EDTA K3 1</td><td>80</td><td>0.05</td><td>0.00</td><td>6.3%</td><td>0.01</td><td>15.2%</td><td>0.00</td><td>4.6%</td><td>0.01</td><td>17.1%</td></tr><tr><td>Sodium Citrate 1</td><td>80</td><td>0.05</td><td>0.00</td><td>6.7%</td><td>0.01</td><td>14.0%</td><td>0.00</td><td>0.0%</td><td>0.01</td><td>15.5%</td></tr><tr><td>Sodium Heparin 1</td><td>80</td><td>0.05</td><td>0.00</td><td>6.7%</td><td>0.01</td><td>12.6%</td><td>0.00</td><td>5.6%</td><td>0.01</td><td>15.4%</td></tr><tr><td>Lithium Heparin 1</td><td>80</td><td>0.05</td><td>0.00</td><td>6.7%</td><td>0.01</td><td>14.5%</td><td>0.00</td><td>7.6%</td><td>0.01</td><td>17.7%</td></tr><tr><td>ACD A</td><td>80</td><td>0.05</td><td>0.00</td><td>6.3%</td><td>0.01</td><td>14.0%</td><td>0.00</td><td>0.4%</td><td>0.01</td><td>15.3%</td></tr><tr><td>Serum 2</td><td>80</td><td>0.55</td><td>0.02</td><td>3.7%</td><td>0.02</td><td>4.0%</td><td>0.02</td><td>3.6%</td><td>0.04</td><td>6.5%</td></tr><tr><td>EDTA K2 2</td><td>80</td><td>0.66</td><td>0.02</td><td>3.5%</td><td>0.03</td><td>4.9%</td><td>0.03</td><td>5.3%</td><td>0.05</td><td>8.0%</td></tr><tr><td>EDTA K3 2</td><td>80</td><td>0.65</td><td>0.02</td><td>3.3%</td><td>0.04</td><td>6.1%</td><td>0.03</td><td>4.7%</td><td>0.05</td><td>8.3%</td></tr><tr><td>Sodium Citrate 2</td><td>80</td><td>0.65</td><td>0.03</td><td>5.0%</td><td>0.03</td><td>5.0%</td><td>0.02</td><td>3.8%</td><td>0.05</td><td>8.0%</td></tr><tr><td>Sodium Heparin 2</td><td>80</td><td>0.57</td><td>0.01</td><td>2.5%</td><td>0.02</td><td>3.7%</td><td>0.03</td><td>4.8%</td><td>0.04</td><td>6.6%</td></tr><tr><td>Lithium Heparin 2</td><td>80</td><td>0.57</td><td>0.02</td><td>2.7%</td><td>0.04</td><td>6.1%</td><td>0.02</td><td>4.0%</td><td>0.05</td><td>7.8%</td></tr><tr><td>ACD 2</td><td>80</td><td>0.68</td><td>0.03</td><td>5.2%</td><td>0.04</td><td>6.3%</td><td>0.03</td><td>4.4%</td><td>0.06</td><td>9.2%</td></tr><tr><td>Serum 3</td><td>80</td><td>1.33</td><td>0.03</td><td>2.1%</td><td>0.06</td><td>4.8%</td><td>0.06</td><td>5.2%</td><td>0.09</td><td>7.4%</td></tr><tr><td>EDTA K2 3</td><td>80</td><td>1.44</td><td>0.03</td><td>2.5%</td><td>0.06</td><td>4.8%</td><td>0.06</td><td>4.7%</td><td>0.09</td><td>7.2%</td></tr><tr><td>EDTA K3 3</td><td>80</td><td>1.35</td><td>0.07</td><td>6.2%</td><td>0.07</td><td>5.4%</td><td>0.05</td><td>4.5%</td><td>0.11</td><td>9.4%</td></tr><tr><td>Sodium Citrate 3</td><td>80</td><td>1.44</td><td>0.04</td><td>3.1%</td><td>0.05</td><td>4.2%</td><td>0.06</td><td>5.2%</td><td>0.09</td><td>7.4%</td></tr><tr><td>Sodium Heparin 3</td><td>80</td><td>1.36</td><td>0.02</td><td>2.1%</td><td>0.06</td><td>5.1%</td><td>0.06</td><td>4.7%</td><td>0.09</td><td>7.2%</td></tr><tr><td>Lithium Heparin 3</td><td>80</td><td>1.35</td><td>0.05</td><td>4.1%</td><td>0.07</td><td>5.8%</td><td>0.05</td><td>4.3%</td><td>0.10</td><td>8.3%</td></tr><tr><td>ACD 3</td><td>80</td><td>1.47</td><td>0.04</td><td>3.5%</td><td>0.10</td><td>8.4%</td><td>0.06</td><td>5.1%</td><td>0.13</td><td>10.5%</td></tr></table>

NA $:$ Not Applicable Within Run: variability of the assay performance from replicate to replicate Between Run: variability of the assay performance from Run to Run il Total :total variability of the assay performance includes within run, between run and between day.

Reproducibility Study:

A 6 member panel consisting of diluted plasma specimens (negative and different levels of positive) was tested in triplicate, once a day for 3 days on 3 lots\* of MONOLISA™ Anti-HAV IgM EIA at 3 separate clinical trial sites.

Each panel was coded with a different number on each day tested in order to blind the operator to the expected value of the sample.

\* :3 different lots were used at the Bio-Rad site and 2 lots were used on each of the external sites. The data from all reagent lots and sites were combined to obtain standard deviation (SD) and pt cefficnvtnwit eny bee o,be total variance.

The data were analyzed acording to the principles described in the Clinical Laboratory Standards Institute guidance EP5-A2, revised November 2004 and ISO/TR 22971:2005. The PROC GLM procedure in ${ \mathsf { S A S } } ^ { \otimes }$ n $\bumpeq$ site $^ +$ lot (site) $^ +$ day (lot site) $^ +$ error.

The summaries are shown in the following tables:

Table 17: MONOLISA™ Anti-HAV IgM EIA Reproducibility Results by Panel Member Signal to Cutoff (S/CO)   

<table><tr><td rowspan="2">Test site</td><td>Panel Member</td><td rowspan="2">N</td><td rowspan="2">Mean</td><td colspan="2">Within Run1</td><td colspan="2">Between Day^{2</td><td colspan="2">Between Lot³</td><td colspan="2">Total4</td></tr><tr><td>S/CO</td><td>SD</td><td>%CV</td><td>SD</td><td>%CV</td><td>SD</td><td>%CV</td><td>SD %CV</td></tr><tr><td rowspan="5">Site #1</td><td>P1</td><td>18</td><td>0.05</td><td>0.03</td><td>74.6</td><td>$\fra5 }$</td><td>0</td><td>$\r5 }$</td><td>0</td><td>0.03</td><td>74.6</td></tr><tr><td>P2</td><td>18</td><td>0.69</td><td>0.03</td><td>4.7</td><td>0.06</td><td>8.1</td><td>055}$</td><td>0</td><td>0.06</td><td>9.4</td></tr><tr><td>P3</td><td>18</td><td>1.10</td><td>0.04</td><td>3.6</td><td>0.07</td><td>6.7</td><td>0fr5}$</td><td>0</td><td>0.08</td><td>7.6</td></tr><tr><td>P4</td><td>18</td><td>1.69</td><td>0.05</td><td>2.7</td><td>0.13</td><td>7.6</td><td>055}$</td><td>0</td><td>0.14</td><td>8.1</td></tr><tr><td>P5</td><td>18 18</td><td>3.26</td><td>0.07</td><td>2.2</td><td>0.03</td><td>1.1</td><td>05</td><td>0</td><td>0.08</td><td>2.4</td></tr><tr><td rowspan="5">Site#2</td><td>P6 P1</td><td></td><td>4.19 0.06</td><td>0.19</td><td>4.6</td><td>0.00</td><td>0.0</td><td>0.05</td><td>1.1</td><td>0.20</td><td>4.7</td></tr><tr><td></td><td>18 18</td><td>0.82</td><td>0.00</td><td>6.4</td><td>0.01</td><td>12.2</td><td>0.00</td><td>6.7</td><td>0.01</td><td>15.4</td></tr><tr><td>P2</td><td>18</td><td>1.27</td><td>0.02</td><td>2.8</td><td>0.06</td><td>7.0</td><td>$0fra5}$</td><td>0</td><td>0.06</td><td>7.5</td></tr><tr><td>P3 P4</td><td>18</td><td>2.01</td><td>0.05 0.12</td><td>3.8</td><td>0.08</td><td>6.6</td><td>0.11</td><td>8.6</td><td>0.15</td><td>11.5</td></tr><tr><td>P5</td><td>18</td><td>3.8</td><td>0.15</td><td>5.7 4.0</td><td>0.14 0.20</td><td>7.0</td><td>0f5}$ 055}$</td><td>0</td><td>0.18</td><td>9.1</td></tr><tr><td></td><td>P6</td><td>18</td><td>4.8</td><td>0.14</td><td>2.8</td><td>0.38</td><td>5.2 7.9</td><td>$\qra5}$</td><td>0 0</td><td>0.25</td><td>6.6</td></tr><tr><td rowspan="5">Site #3</td><td>P1</td><td>27</td><td>0.04</td><td>0.00</td><td>6.7</td><td>0.01</td><td>13.0</td><td>0.00</td><td>11.7</td><td>0.40</td><td>8.3</td></tr><tr><td>P2</td><td>27</td><td></td><td>0.71</td><td>0.02</td><td>3.3</td><td>0.03</td><td>4.0</td><td></td><td></td><td>0.01</td><td>18.7</td></tr><tr><td>P3</td><td>27</td><td>1.12</td><td></td><td></td><td></td><td></td><td>2.1</td><td>0.04 0.09</td><td>6.1</td><td>0.06</td><td>8.0</td></tr><tr><td>P4</td><td>27</td><td>1.77</td><td>0.05 0.06</td><td>4.3 3.4</td><td>0.02 0.08</td><td>4.3</td><td></td><td>0.10</td><td>7.7</td><td>0.10</td><td>9.1</td></tr><tr><td>P5</td><td>27</td><td>3.26</td><td>0.09</td><td>2.8</td><td></td><td></td><td></td><td></td><td>5.8</td><td>0.14</td><td>8.0</td></tr><tr><td></td><td></td><td></td><td></td><td>0.10</td><td>2.6</td><td>0.10 0.10</td><td>3.1</td><td>0.13</td><td>4.0</td><td>0.19</td><td></td><td>5.8</td></tr><tr><td></td><td>P6</td><td>27</td><td>3.93</td><td></td><td></td><td></td><td></td><td>2.5</td><td>0.20</td><td>5.1</td><td>0.25</td><td>6.3</td></tr></table>

1Within Run:variability of the assay performance from replicate to replicate Between Day: variability of the assay performance from Day to Day 3Been Lotvariability of the assy performan om Lot o Lot Total total variability of the assay performance includes within run, between day and between lot. 5 Negative variances were rounded to zero, per statistical convention.

# BIO RAD

Table 18: MONOLISA™M Anti-HAV IgM EIA Reproducibility summary by Panel Member Signal to Cutoff (S/CO).   

<table><tr><td rowspan="2">Panel Member</td><td rowspan="2">N</td><td rowspan="2">Mean S/CO</td><td colspan="2">Within Run1</td><td colspan="2">Between Day^{2</td><td colspan="2">Between Lot³</td><td colspan="2">Between Site5</td><td rowspan="2">Total4</td></tr><tr><td>SD</td><td>%CV</td><td>SD</td><td>%CV</td><td>SD</td><td>%CV SD</td><td>%CV</td><td>SD %CV</td></tr><tr><td>P1</td><td>63</td><td>0.05</td><td>0.02</td><td>37.8</td><td>0.00</td><td>0.0</td><td>0.00</td><td>8.1</td><td>0.01</td><td>19.6</td><td>0.02</td><td>43.3</td></tr><tr><td>P2</td><td>63</td><td>0.74</td><td>0.03</td><td>3.6</td><td>0.05</td><td>6.4</td><td>0.02</td><td>2.6</td><td>0.06</td><td>8.0</td><td>0.08</td><td>11.1</td></tr><tr><td>P3</td><td>63</td><td>1.16</td><td>0.05</td><td>3.9</td><td>0.06</td><td>5.3</td><td>0.08</td><td>6.8</td><td>0.07</td><td>5.8</td><td>0.13</td><td>11.1</td></tr><tr><td>P4</td><td>63</td><td>1.82</td><td>0.08</td><td>4.2</td><td>0.11</td><td>6.3</td><td>0.05</td><td>3.0</td><td>0.15</td><td>8.1</td><td>0.21</td><td>11.5</td></tr><tr><td>P5</td><td>63</td><td>3.41</td><td>0.11</td><td>3.0</td><td>0.13</td><td>3.7</td><td>0.09</td><td>2.5</td><td>0.29</td><td>8.5</td><td>0.35</td><td>10.1</td></tr><tr><td>P6</td><td>63</td><td>4.25</td><td>0.14</td><td>3.3</td><td>0.21</td><td>5.0</td><td>0.14</td><td>3.2</td><td>0.43</td><td>10.1</td><td>0.52</td><td>12.2</td></tr></table>

Within Run:variability of the assay performance from replicate to replicate 3Been Lot:variabiity  the assy perforan om Lot o Lot

Reproducibility study on Negative and Positive Controls:

The negative ad positive controls were tested n triplicate,once a day by 3 different operators 3 days. The data were analyzed according to the principles described in the Clinical Laboratory Standards Institute guidance EP5-A2, revised November 2004 and ISO/TR 22971:2005.

Table 19 : MONOLISA™M Anti-HAV IgM EIA Control Reproducibility summary by Operator by Signal to Cutoff (S/CO).   

<table><tr><td rowspan="2">Samples</td><td rowspan="2">N</td><td rowspan="2">Mean</td><td colspan="2">Within Run1</td><td colspan="2">Between Day^}$</td><td colspan="2">Between Opeperator 3</td><td colspan="2">Total4</td></tr><tr><td>SD</td><td>%CV</td><td>SD</td><td>%CV</td><td>SD</td><td>%CV</td><td>SD</td><td>%CV</td></tr><tr><td>Negative Control</td><td>27</td><td>0.06</td><td>0.02</td><td>24.2</td><td>0.02</td><td>23.3</td><td>$\fr53}$</td><td>0</td><td>0.02</td><td>N/A</td></tr><tr><td>Positive Control</td><td>27</td><td>1.91</td><td>0.08</td><td>4.1</td><td>0.02</td><td>0.9</td><td>$0fra5}$</td><td>0</td><td>0.08</td><td>4.17</td></tr></table>

1 Within Run: variability of the assay performance from replicate to replicate 2Between Day: variability of the assay performance from Day to Day Been Operator:variability h ssay peroran ro Operator Opr l i e 5Negative variances were rounded to zero, per statistical convention.

Manuela Kaul   
RA-Manager   
Bio-Rad France   
3, Boulevard Raymond Poincaré   
92430 Marnes-la-Coquette, France

Re: k063319 Trade/Device Name: MONOLISA™M Anti-HAV IgM EIA Regulation Number: 21 CFR 866.3310 Regulation Name: Hepatitis A Virus (HAV) Serological Reagents Regulatory Class: Class II Product Code: LOL Dated: March 21, 2007 Received: April 3, 2007

Dear Ms. Kaul:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

![](images/92b45c4cae41a1d187f66520c4b634c0bf620dcaa61f01311985568ad4d8f651.jpg)

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices Office of In Vitro Diagnostic Devices Evaluation and Safety   
Center for Devices and   
Radiological Health

Device Name: MONOLISATM Anti-HAV IgM EIA

# Indications for Use:

The MONOLISA™ Anti-HAV IgM EIA is an in vitro enzyme immuoassay kit intended or use i e qualitative detection of IgM antibodies to Hepatitis A virus (anti-HAV IgM) in human (adult and pediatric) serum or plasma (EDTA, Heparin, Citrate, ACD). This assay is indicated for testing specimens from individuals who have signs and symptoms consistent with acute Hepatitis. Assay results, in conjunction with other serological or clinical information, may be used for the laboratory diagnosis of individuals with acute or recent Hepatitis A.

Assay performance characteristics have not been established for immunocompromised or immunosuppressed patients, and cord blood or neonatal specimens

WARNiNG :This assay is not intended for screening blood or solid or soft tissue donors.

Concurrence of CDRH, Office of Device Evaluation (ODE)

Nall a   
Division Sign-Off   
Office of In Vitro Diagnostic   
Device Evaluation and Safety   
5100 K063319 2-T